Effects of peptidic antagonists of Grb2-SH2 on human breast cancer cells

Protein and Peptide Letters

Volumn 17, Issue 1, 2010, Pages 44-53

  Chen, Chiu Heng ^a   Chen, Meng Kai ^a   Jeng, Kee Ching G ^b   Lung, Feng Di T ^a  

^a TUNGHAI UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Cell cycle; Cell viability; Cytotoxicity; Human breast cancer cell line; Peptide

Indexed keywords

CYCLOPEPTIDE; GRB2 PROTEIN, HUMAN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; IMMOBILIZED PROTEIN; PEPTIDE;

ARTICLE; BREAST TUMOR; CELL CYCLE; CELL GROWTH; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; KINETICS; METABOLISM; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRB2 ADAPTOR PROTEIN; HUMANS; IMMOBILIZED PROTEINS; KINETICS; PEPTIDES; PEPTIDES, CYCLIC; PROTEIN STRUCTURE, TERTIARY;

EID: 77949924145     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986610789909421     Document Type: Article

References (47)

1. Garbay, C.; Liu, W. Q.; Vidal, M.; Roques, B. P. Inhibitors of Ras signal transduction as antitumor agents. Biochem. Pharmacol., 2000, 60(8), 1165-9.
2. Pawson, T. Protein-tyrosine kinases. Getting down to specifics. Nature, 1995, 373(6514), 477-8.
3. Shakespeare, W. C. SH2 domain inhibition: a problem solved? Curr. Opin. Chem. Biol., 2001, 5(4), 409-15.
4. Silvennoinen, O.; Schindler, C.; Schlessinger, J.; Levy, D. E. Rasindependent growth factor signaling by transcription factor tyrosine phosphorylation. Science, 1993, 261(5129), 1736-9.
5. Cohen, G. B.; Ren, R.; Baltimore, D. Modular binding domains in signal transduction proteins. Cell, 1995, 80(2), 237-48.
6. Pawson, T.; Scott, J. D. Signaling through scaffold, anchoring, and adaptor proteins. Science, 1997, 278(5346), 2075-80.
7. Mayer, B. J.; Gupta, R. Functions of SH2 and SH3 domains. Curr. Top. Microbiol. Immunol., 1998, 228, 1-22.
8. Wei, C. Q.; Li, B.; Guo, R.; Yang, D.; Burke, T. R. Jr. Development of a phosphatase-stable phosphotyrosyl mimetic suitably protected for the synthesis of high-affinity Grb2 SH2 domain-binding ligands. Bioorg. Med. Chem. Lett., 2002, 12(19), 2781-4.
9. Li, P.; Zhang, M.; Peach, M. L.; Zhang, X.; Liu, H.; Nicklaus, M.; Yang, D.; Roller, P. P. Structural basis for a non-phosphoruscontaining cyclic peptide binding to Grb2-SH2 domain with high affinity. Biochem. Biophys. Res. Commun., 2003, 307(4), 1038-44.
10. Jiang, S.; Li, P.; Peach, M. L.; Bindu, L.; Worthy, K. W.; Fisher, R. J.; Burke, T. R. Jr.; Nicklaus, M.; Roller, P. P. Structure-based design of potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics. Biochem. Biophys. Res. Commun., 2006, 349(2), 497-503.
11. Song, Y. L.; Peach, M. L.; Roller, P. P.; Qiu, S.; Wang, S.; Long, Y. Q. Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3'-substituted tyrosine derivatives. J. Med. Chem., 2006, 49(5), 1585-96.
12. Maignan, S.; Guilloteau, J. P.; Fromage, N.; Arnoux, B.; Becquart, J.; Ducruix, A. Crystal structure of the mammalian Grb2 adaptor. Science, 1995, 268(5208), 291-3.
13. Lowenstein, E. J.; Daly, R. J.; Batzer, A. G.; Li, W.; Margolis, B.; Lammers, R.; Ullrich, A.; Skolnik, E. Y.; Bar-Sagi, D.; Schlessinger, J. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell, 1992, 70(3), 431-42.
14. Smithgall, T. E. SH2 and SH3 domains: potential targets for anticancer drug design. J. Pharmacol. Toxicol. Methods, 1995, 34(3), 125-32.
15. Fretz, H.; Furet, P.; Garcia-Echeverria, C.; Schoepfer, J.; Rahuel, J. Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways. Curr. Pharm. Des., 2000, 6(18), 1777-96.
16. Lung, F. D.; Tsai, J. Y.; Wei, S. Y.; Cheng, J. W.; Chen, C.; Li, P.; Roller, P. P. Novel peptide inhibitors for Grb2 SH2 domain and their detection by surface plasmon resonance. J. Pept. Res., 2002, 60(3), 143-9.
17. Lung, F. D.; Tsai, J. Y. Grb2 SH2 domain-binding peptide analogs as potential anticancer agents. Biopolymers, 2003, 71(2), 132-40.
18. Lung, F. D.; Chang, C. W.; Chong, M. C.; Liou, C. C.; Li, P.; Peach, M. L.; Nicklaus, M. C.; Lou, B. S.; Roller, P. P. Small nonphosphorylated Grb2-SH2 domain antagonists evaluated by surface plasmon resonance technology. Biopolymers, 2005, 80(5), 628-35.
19. Buckley, C. D.; Pilling, D.; Henriquez, N. V.; Parsonage, G.; Threlfall, K.; Scheel-Toellner, D.; Simmons, D. L.; Akbar, A. N.; Lord, J. M.; Salmon, M. RGD peptides induce apoptosis by direct caspase-3 activation. Nature, 1999, 397(6719), 534-9.
20. Sulyok, G. A.; Gibson, C.; Goodman, S. L.; Holzemann, G.; Wiesner, M.; Kessler, H. Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists. J. Med. Chem., 2001, 44(12), 1938-50.
21. van Hagen, P. M.; Breeman, W. A.; Bernard, H. F.; Schaar, M.; Mooij, C. M.; Srinivasan, A.; Schmidt, M. A.; Krenning, E. P.; de Jong, M. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int. J. Cancer, 2000, 90(4), 186-98.
22. Arap, W.; Pasqualini, R.; Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 1998, 279(5349), 377-80.
23. Merrifield, R. B. Solid-phase peptide synthesis. Adv. Enzymol. Relat. Areas. Mol. Biol., 1969, 32, 221-96.
24. Meienhofer, J.; Waki, M.; Heimer, E. P.; Lambros, T. J.; Makofske, R. C.; Chang, C. D. Solid phase synthesis without repetitive acidolysis. Preparation of leucyl-alanyl-glycyl-valine using 9- fluorenylmethyloxycarbonylamino acids. Int. J. Pept. Protein Res., 1979, 13(1), 35-42.
25. Sastry, L.; Lin, W.; Wong, W. T.; Di Fiore, P. P.; Scoppa, C. A.; King, C. R. Quantitative analysis of Grb2-Sos1 interaction: the Nterminal SH3 domain of Grb2 mediates affinity. Oncogene, 1995, 11(6), 1107-12.
26. Lung, F. D.; Li, W. C.; Chang, Y. H.; Chen, H. M. Determination of binding potency of peptidic inhibitors of Grb2-SH2 by using the protein-captured biosensor method. Protein. Pept. Lett., 2008, 15(8), 808-10.
27. Pelicci, G.; Lanfrancone, L.; Grignani, F.; McGlade, J.; Cavallo, F.; Forni, G.; Nicoletti, I.; Pawson, T.; Pelicci, P. G. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell, 1992, 70(1), 93-104.
28. Rozakis-Adcock, M.; McGlade, J.; Mbamalu, G.; Pelicci, G.; Daly, R.; Li, W.; Batzer, A.; Thomas, S.; Brugge, J.; Pelicci, P. G.; Schlessinger, J.; Pawson, T. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature, 1992, 360(6405), 689-92.
29. Gale, N. W.; Kaplan, S.; Lowenstein, E. J.; Schlessinger, J.; Bar-Sagi, D. Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras. Nature, 1993, 363(6424), 88-92.
30. Egan, S. E.; Giddings, B. W.; Brooks, M. W.; Buday, L.; Sizeland, A. M.; Weinberg, R. A. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature, 1993, 363(6424), 45-51.
31. Buday, L.; Downward, J. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell, 1993, 73(3), 611-20.
32. Schlaepfer, D. D.; Hanks, S. K.; Hunter, T.; van der Geer, P. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature, 1994, 372(6508), 786-91.
33. Goudreau, N.; Cornille, F.; Duchesne, M.; Parker, F.; Tocque, B.; Garbay, C.; Roques, B. P. NMR structure of the N-terminal SH3 domain of GRB2 and its complex with a proline-rich peptide from Sos. Nat. Struct. Biol., 1994, 1 (12), 898-907.
34. Pendergast, A. M.; Gishizky, M. L.; Havlik, M. H.; Witte, O. N. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol. Cell Biol., 1993, 13(3), 1728-36.
35. McCormick, F. Signal transduction. How receptors turn Ras on. Nature, 1993, 363 (6424), 15-6.
36. Janes, P. W.; Daly, R. J.; deFazio, A.; Sutherland, R. L. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene, 1994, 9(12), 3601-8.
37. Daly, R. J.; Binder, M. D.; Sutherland, R. L. Overexpression of the Grb2 gene in human breast cancer cell lines. Oncogene, 1994, 9(9), 2723-7.
38. Oligino, L.; Lung, F. D.; Sastry, L.; Bigelow, J.; Cao, T.; Curran, M.; Burke, T. R. Jr.; Wang, S.; Krag, D.; Roller, P. P.; King, C. R. Nonphosphorylated peptide ligands for the Grb2 Src homology 2 domain. J. Biol. Chem., 1997, 272(46), 29046-52.
39. Songyang, Z.; Shoelson, S. E.; McGlade, J.; Olivier, P.; Pawson, T.; Bustelo, X. R.; Barbacid, M.; Sabe, H.; Hanafusa, H.; Yi, T.; Ran, R.; Baltimore, D.; Ratnofsky, S.; Feldman, R.A.; Cantley, L.C. Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol. Cell Biol., 1994, 14(4), 2777-85.
40. Lung, F. D.; Long, Y. Q.; Roller, P. P.; King, C. R.; Varady, J.; Wu, X. W.; Wang, S. Functional preference of the constituent amino acid residues in a phage-library-based nonphosphorylated inhibitor of the Grb2-SH2 domain. J. Pept. Res., 2001, 57(6), 447-54.
41. Furet, P.; Gay, B.; Garcia-Echeverria, C.; Rahuel, J.; Fretz, H.; Schoepfer, J.; Caravatti, G. Discovery of 3-aminobenzyloxycarbonyl as an N-terminal group conferring high affinity to the minimal phosphopeptide sequence recognized by the Grb2-SH2 domain. J. Med. Chem., 1997, 40(22), 3551-6.
42. Dankort, D. L.; Wang, Z.; Blackmore, V.; Moran, M. F.; Muller, W. J. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Mol. Cell Biol., 1997, 17(9), 5410-25.
43. Hart, C. P.; Martin, J. E.; Reed, M. A.; Keval, A. A.; Pustelnik, M. J.; Northrop, J. P.; Patel, D. V.; Grove, J. R. Potent inhibitory ligands of the GRB2 SH2 domain from recombinant peptide libraries. Cell Signal, 1999, 11(6), 453-64.
44. De Filippis, V.; De Antoni, F.; Frigo, M.; Polverino de Laureto, P.; Fontana, A. Enhanced protein thermostability by Ala-->Aib replacement. Biochemistry, 1998, 37(6), 1686-96.
45. Myszka, D. G.; Wood, S. J.; Biere, A. L. Analysis of fibril elongation using surface plasmon resonance biosensors. Methods Enzymol., 1999, 309, 386-402.
46. Akazawa, A.; Nishikawa, K.; Suzuki, K.; Asano, R.; Kumadaki, I.; Satoh, H.; Hagiwara, K.; Shin, S. J.; Yano, T. Induction of apoptosis in a human breast cancer cell overexpressing ErbB-2 receptor by alpha-tocopheryloxybutyric acid. Jpn. J. Pharmacol., 2002, 89 (4), 417-21.
47. Saceda, M.; Grunt, T. W.; Colomer, R.; Lippman, M. E.; Lupu, R.; Martin, M. B. Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines. Endocrinology, 1996, 137 (10), 4322-30.